Integration of the pRB and p53 cell cycle control pathways

Journal of Neuro-Oncology

Volumn 51, Issue 3, 2001, Pages 183-204

  Stewart, Craig L ^a   Soria, Alejandro Moro ^a,b   Hamel, Paul A ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cell cycle; Cell death; Cell growth; P53; PRB; Tumor suppressor gene

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; DNA; PROTEIN MDM2; PROTEIN P21; PROTEIN P27; PROTEIN P53; PROTEIN P57; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F;

APOPTOSIS; BINDING AFFINITY; CANCER; CARCINOGENESIS; CELL CYCLE; CELL CYCLE PHASE; CELL DIFFERENTIATION; CELL GROWTH; DNA DAMAGE; DNA REPAIR; DNA SYNTHESIS; ENZYME ACTIVITY; FEEDBACK SYSTEM; GENE LOCUS; GENE MUTATION; GENETIC ANALYSIS; GROWTH INHIBITION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MITOGENESIS; MOLECULAR INTERACTION; NONHUMAN; PHASE TRANSITION; PROTEIN DNA INTERACTION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; RETINOBLASTOMA; REVIEW; TRANSACTIVATION; TRANSCRIPTION INITIATION; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL CYCLE; CELL DEATH; CELL DIVISION; CHROMOSOME MAPPING; HUMANS; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035020051     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1010615822317     Document Type: Review

References (270)

1. Nurse P: Universal control mechanism regulating onset of M-phase. Nature 344: 503-508, 1990
2. Pardee AB: A restriction point for control of normal animal proliferation. Proc Natl Acad Sci USA 71: 1286-1290, 1974
3. Hatakeyama M, Brill JA, Fink GR, Weinberg RA: Collaboration of G1 cyclins in the functional inactivation of the retinoblastoma protein. Genes Dev 8: 1759-1771, 1994
4. Horton LE, Qian Y, Templeton DJ: G1 cyclins control the retinoblastoma gene product growth regulation activity via upstream mechanisms. Cell Growth Differ 6: 395-407, 1995
5. Sherr CJ: Mammalian G1 cyclins. Cell 73: 1059-1065, 1993
6. Arber N, Doki Y, Han EK, Sgambato A, Zhou P, Kim NH, Delohery T, Klein MG, Holt PR, Weinstein IB: Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res 57: 1569-1574, 1997
7. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G: Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 7: 812-821, 1993
8. Duronio RJ, O'Farrell PH: Developmental control of the G1 to S transition in Drosophila: cyclin E is a limiting downstream target of E2F. Genes Dev 9: 1456-1468, 1995
9. Duronio RJ, Brook A, Dyson N, O'Farrell PH: E2F-induced S phase requires cyclin E. Genes Dev 10: 2505-2513, 1996
10. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pagano M: Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 15: 2612-2624, 1995
11. Hanna Z, Jankowski M, Tremblay P, Jiang X, Milatovitch A, Francke U, Jolicoeur P: The vin-1 gene, identified by provirus insertional mutatgenesis, is the cyclin D2. Oncogene 8: 1661-1666, 1993
12. Lukas J, Bartkova J, Welcker M, Peterson OW, Peters G, Strauss M, Bartek J: Cyclin D2 is a moderately oscillating nucleoprotein required for G1 phase progression in specific cell types. Oncogene 10: 2125-2134, 1995
13. Lew DJ, Dulic V, Reed SI: Isolation of three novel human cyclins by rescue of G1 cyclin (Cln) function in yeast. Cell 66: 1197-1206, 1991
14. Duronio RJ, O'Farrell PH: Developmental control of the G1 to S transition in Drosophila: cyclin E is a limiting downstream target of E2F. Genes Dev 9: 1456-1468, 1995
15. Kitagawa M, Higashi H, Jung HK, Suzuki TI, Ikeda M, Tamai K, Kato J, Segawa K, Yoshida E, Nishimura S, Taya Y: The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. Embo J 15: 7060-7069, 1996
16. Higashi H, Suzuki-Takahashi I, Taya Y, Segawa K, Nishimura S, Kitagawa M: Differences in substrate specificity between Cdk2-cyclin A and Cdk2-cyclin E in vitro. Biochem Biophys Res Commun 216: 520-525, 1995
17. Bates S, Bonetta L, MacAllan D, Parry D, Holder A, Dickson C, Peters G: CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1. Oncogene 9: 71-79, 1994
18. Matsushime H, Ewen ME, Strom DK, Kato JY, Hanks SK, Roussel MF, Sherr CJ: Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins. Cell 71: 323-334, 1992
19. Meyerson M, Harlow E: Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol 14: 2077-2086, 1994
20. Dulic V, Lees E, Reed SI: Association of human cyclin E with a periodic G1-S phase protein kinase. Science 257: 1958-1961, 1992
21. Koff A, Cross F, Fisher A, Schumacher J, LeGuellec K, Phillippe M, Roberts J: Human cyclin E: a new cyclin that interacts with two members of the CDC2 gene family. Cell 66: 1217-1228, 1991
22. Koff A, Giordano A, Desai D, Yamashita K, Harper JW, Elledge S, Nishimoto T, Morgan DO, Franza BR, Roberts JM: Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science 257: 1689-1694, 1992
23. Sherr C: Twelfth Annual Meeting on Oncogenes, Frederick, Maryland, 1996
24. Aguzzi A, Kiess M, Rüedi D, Hamel PA: Cyclins D1, D2 and D3 are expressed in distinct tissues during mouse embryogenesis. Transgenics 2: 29-39, 1996
25. Sicinski P, Donaher JL, Parker SB, Li T, Fazeli A, Gardner H, Haslam SZ, Bronson RT, Elledge SJ, Weinberg RA: Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 82: 621-630, 1995
26. Sicinski P, Donaher JL, Geng Y, Parker SB, Gardner H, Park MY, Robker RL, Richards JS, McGinnis LK, Biggers JD, Eppig JJ, Bronson RT, Elledge SJ, Weinberg RA: Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature 384: 470-474, 1996
27. Zhao JZ, Nornes HO, Neuman T: Expression of RB, E2F1, cdc2, and D-cyclins, and B-cyclins in developing spinal-cord. Neuroscience letters 191: 49-52, 1995
28. Kiess M, Gill RM, Hamel PA: Expression of the positive regulator of cell cycle progression, cyclin D3, is induced during differentiation of myoblasts into quiescent myotubes. Oncogene 10: 159-166, 1995
29. Della RF, Borriello A, Mastropietro S, Della PV, Monno F, Gabutti V, Locatelli F, Bonsi L, Bagnara GP, Iolascon A: Expression of G1-phase cell cycle genes during hematopoietic lineage. Biochem Biophys Res Commun 231: 73-76, 1997
30. Sicinski P, Donaher JL, Parker SB, Li T, Fazeli A, Gardner H, Haslam SZ, Bronson RT, Elledge SJ, Weinberg RA: Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 82: 621-630, 1995
31. Sicinski P, Donaher JL, Geng Y, Parker SB, Gardner H, Park MY, Robker RL, Richards JS, McGinnis LK, Biggers JD, Eppig JJ, Bronson RT, Elledge SJ, Weinberg RA: Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature 384: 470-474, 1996
32. Rao SS, Chu C, Kohtz DS: Ectopic expression of cyclin D1 prevents activation of gene transcription by myogenic basic helix-loop-helix regulators. Mol Cell Biol 14: 5259-5267, 1994
33. Kato J-Y, Sherr CJ: Inhibition of granulocyte differentiation by G1 cyclins D2 and D3 but not D1. Proc Natl Acad Sci USA 90: 11513-11517, 1993
34. Rao SS, Kohtz DS: Positive and negative regulation of D-type cyclin expression in skeletal myoblasts by basic fibroblast growth factor and transforming growth factor b. A role for cyclin D1 in control of myoblast differentiation. J Biol Chem 270: 4093-4100, 1995
35. Cenciarelli C, De Santa F, Puri PL, Mattei E, Ricci L, Bucci F, Felsani A, Caruso M: Critical role played by cyclin D3 in the MyoD-mediated arrest of cell cycle during myoblast differentiation (in process citation). Mol Cell Biol 19: 5203-5217, 1999
36. Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, Dryja TP: A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323: 643-646, 1986
37. Buchkovich K, Duffy LA, Harlow E: The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell 58: 1097-1105, 1989
38. Chen PL, Scully P, Shew JY, Wang JY, Lee WH: Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell 58: 1193-1198, 1989
39. Mihara K, Cao XR, Yen A, Chandler S, Driscoll B, Murphree AL, TAng A and Fung YK: Cell cycle-dependent regulation of phosphorylation of the human retinoblastoma gene product. Science 246: 1300-1303, 1989
40. DeCaprio JA, Ludlow JW, Lynch D, Furukawa Y, Griffin J, Piwnica WH, Huang CM, Livingston DM: The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. Cell 58: 1085-1095, 1989
41. Kato J, Matsushime H, Hiebert SW, Ewen ME, Sherr CJ: Direct binding of cyclin D to the retinoblastoma gene product (pRB) and pRB phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 7: 331-342, 1993
42. Ewen ME, Sluss HK, Sherr CJ, Matsushime H, Kato J, Livingston DM: Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 73: 487-497, 1993
43. Xiao Z-X, Ginsberg D, Ewen M, Livingston D: Regulation of the retinoblastoma protein-related protein p107 by G1 cyclin-associated kinases. Proc Natl Acad Sci USA 93: 4633-4637, 1996
44. Hinds PW, Mittnacht S, Dulic V, Arnold A, Reed SI, Weinberg RA: Regulation of retinoblastoma functions by ectopic expression of human cyclins. Cell 70: 993-1006, 1992
45. Dowdy SF, Hinds PW, Louie K, Reed SI, Arnold A, Weinberg RA: Physical interaction of the retinoblastoma protein with human D cyclins. Cell 73: 499-511, 1993
46. Mittnacht S, Weinberg RA: G1/S phosphorylation of the retinoblastoma protein is associated with an altered affinity for the nuclear compartment. Cell 65: 381-393, 1991
47. Hamel PA, Gill M, Phillips RA, Gallie BL: Regions controlling hyper-phosphorylation and conformation of the retinoblastoma gene product are independent of domains required for transcriptional repression. Oncogene 7: 693-701, 1992
48. Hamel PA, Gill RM, Phillips RA, Gallie BL: Transcriptional repression of the E2-containing promoters EIIaE, c-myc and RB1 by the product of the RB1 gene. Mol Cell Biol 12: 3431-3438, 1992
49. Chang MW, Barr E, Seltzer J, Jiang Y-Q, Nabel GJ, Nabel E, Parmacek MS and Leiden JM: Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 267: 518-522, 1995
50. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA: Effects of an Rb mutation in the mouse. Nature 359: 295-300, 1992
51. Almasan A, Yin YX, Kelly RE, Lee E, Bradley A, Li WW, Bertino JR, Wahl GM: Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis. Proc Natl Acad Sci USA 92: 5436-5440, 1995
52. Shan B, Durfee T, Lee W-H: Disruption of RB/E2F-1 interaction by single point mutations in E2F-1 enhances S-phase entry and apoptosis. Proc Natl Acad Sci USA 93: 679-684, 1996
53. Lee EYHP, Chang CY, Hu N, Wang YCJ, Lai CC, Herrup K, Lee WH, Bradley A: Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature 359: 288-294, 1992
54. Slack RS, Skerjanc IS, Lach B, Craig J, Jardine K, McBurney MW: Cells differentiating into neuralectoderm undergo apoptosis in the absence of functional retinoblastoma family proteins. J Cell Biol 129: 779-788, 1995
55. Schneider JW, Gu W, Zhu L, Mahdavi V, Nadal-Ginard B: Reversal of terminal differentiation mediated by p107 in Rb-/- muscle cells. Science 264: 1467-1471, 1994
56. Mulligan GJ, Wong J, Jacks T: p130 is dispensable in peripheral T lymphocytes: evidence for functional compensation by p107 and pRB. Mol Cell Biol 18: 206-220, 1998
57. Robanus-Maandag E, Dekker M, van der Valk M, Carrozza ML, Jeanny JC, Dannenberg JH, Berns A, te Riele H: p107 is a suppressor of retinoblastoma development in pRb-deficient mice. Genes Dev 12: 1599-1609, 1998
58. Cobrinik D, Lee M-H, Hannon G, Mulligan G, Bronson RT, Dyson N, Harlow E, Beach D, Weinberg RA, Jacks T: Shared role of the pRB-related p130 and p107 proteins in limb development. Genes Dev 10: 1633-1644, 1996
59. Lee M-H, Williams BO, Mulligan G, Mukai S, Bronson RT, Dyson N, Harlow E, Jacks T: Targeted disruption of p107: functional overlap between p107 and RB. Genes Dev 10: 1621-1632, 1996
60. Claudio PP, Howard CM, Baldi A, De Luca A, Fu Y, Conorelli G, Sun Y, Colburn N, Calabretta B, Giordano A: p130/pRb2 has growth suppressive properties similar to yet distinctive from those of retinoblastoma family members pRb and p107. Cancer Res 54: 5556-5560, 1994
61. Ewen ME, Xing YG, Lawrence JB, Livingston DM: Molecular cloning, chromosomal mapping, and expression of the cDNA for p107, a retinoblastoma gene product-related protein. Cell 66: 1155-1164, 1991
62. Grana X, Garriga J, Mayol X: Role of the retinoblastoma protein family, pRB, p107 and p130 in the negative control of cell growth. Oncogene 17: 3365-3383, 1998
63. Beijersbergen RL, Carlee L, Kerkhoven RM, Bernards R: Regulation of the retinoblastoma protein-related p107 by G1 cyclin complexes. Genes Dev 9: 1340-1353, 1995
64. Knudsen ES, Wang JY: Hyperphosphorylated p107 and p130 bind to T-antigen: identification of a critical regulatory sequence present in RB but not in p107/p130. Oncogene 16: 1655-1663, 1998
65. Zhu L, Enders G, Lees JA, Beijersbergen RL, Bernards R, Harlow E: The pRB-related protein p107 contains two growth suppression domains: independent interactions with E2F and cyclin/cdk complexes. Embo J 14: 1904-1913, 1995
66. Zamanian M, La Thangue NB: Transcriptional repression by the Rb related protein p107. Mol Biol Cell 4: 389-396, 1993
67. Zhu L, van den Heuvel S, Helin K, Fattaey A, Ewen M, Livingston D, Dyson N, Harlow E: Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein. Genes Dev 7: 1111-1125, 1993
68. Li Y, Graham C, Lacy S, Duncan AMV, Whyte P: The adenovirus Ela-associated 130-kDa protein is encoded by a member of the retinoblastoma gene family and physically interacts with cyclins A and E. Genes Dev 7: 2366-2377, 1993
69. Yeung RS, Bell DW, Testa JR, Mayol, X, Baldi A, Grana X, Klinga LK, Knudson AG, Giordano A: The retinoblastoma-related gene, RB2, maps to human chromosome 16q12 and rat chromosome 19. Oncogene 8: 3465-3468, 1993
70. Mayol X, Grana X, Baldi A, Sang N, Hu Q, Giordano A: Cloning of a new member of the retinoblastoma gene family (pRb2) which binds to the E1A transforming domain. Oncogene 8: 2561-2566, 1993
71. LeCouter JE, Kablar B, Hardy WR, Ying C, Megeney LA, May LL, Rudnicki MA: Strain-dependent myeloid hyperplasia, growth deficiency, and accelerated cell cycle in mice lacking the Rb-related p107 gene. Mol Cell Biol 18: 7455-7465, 1998
72. LeCouter J, Megeney LA, Kablar B, Parker M, Hardy R, Singh G, Rudnicki MA: Severe growth and differentiation deficits in mice lacking p107 and p130. AACR Tumor Suppressor Meeting, Victoria, B. C. 1997.
73. Wiggan O, Taniguchi-Sidle A, Hamel PA: Interaction of the pRB-family proteins with paired-like homeodomains. Oncogene 16: 227-236, 1998
74. Gu W, Schneider JW, Condorelli G, Kaushai S, Mahdavi V, Nadal-Ginard B: Interaction of myogenic factors and the retinblastoma protein mediates muscle cell commitment and differentiation. Cell 72: 309-324, 1993
75. Datta PK, Raychaudhuri P, Bagchi S: Association of p107 with Sp1: genetically separable regions of p107 are involved in regulation of E2F- and Sp1-dependent transcription. Mol Cell Biol 15: 5444-5452, 1995
76. Kim SJ, Onwuta US, Lee YI, Li R, Botchan MR, Robbins PD: The retinoblastoma gene product regulates Sp1-mediated transcription. Mol Cell Biol 12: 2455-2463, 1992
77. van Wijnen AJ, Cooper C, Odgren P, Aziz F, De Luca A, Shakoori RA, Giordano A, Quesenberry PJ, Lian JB, Stein GS, Stein JL: Cell cycle-dependent modifications in activities of pRb-related tumor suppressors and proliferation-specific CDP/cut homeodomain factors in murine hematopoietic progenitor cells. J Cell Biochem 66: 512-523, 1997
78. Buyse IM, Shao G, Huang S: The retinoblastoma protein binds to RIZ, a zinc-finger protein that shares an epitope with the adenovirus E1A protein. Proc Natl Acad Sci USA 92: 4467-4471, 1995
79. Chen P-L, Riley DJ, Chen-Kiang S, Lee W-H: Retinoblastoma protein directly interacts with and activates the transcription factor NF-IL6. Proc Natl Acad Sci USA 93: 465-469, 1996
80. Chen PL, Riley DJ, Chen Y, Lee WH: Retinoblastoma protein positively regulates terminal adipocyte differentiation through direct interaction with C/EBPs. Genes Dev 10: 2794-2804, 1996
81. Cvekl A, Kashanchi F, Brady JN, Piatigorsky J: Pax-6 interactions with TATA-box-binding protein and retinoblastoma protein. Invest Ophthalmol Vis Sci 40: 1343-1350, 1999
82. Dunaief JL, Strober BE, Guha S, Khavari PA, lin K, Luban J, Begemann M, Crabtree GR, Goff SP: The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest. Cell 79: 119-130, 1994
83. Hu Q, Lees JA, Buchkovich KJ, Harlow E: The retinoblastoma protein physically associates with the human cdc2 kinase. Mol Cell Biol 12: 971-980, 1992
84. Iavarone A, Garg P, Lasorella A, Hsu J, Israel MA: The helix-loop-helix protein Id-2 enhances cell proliferation and binds to the retinoblastoma protein. Genes Dev 8: 1270-1284, 1994
85. Inoue A, Torigoe T, Sogahata K, Kamiguchi K, Takahashi S, Sawada Y, Saijo M, Taya Y, Ishii S, Sato N et al.: 70-kDa heat shock cognate protein interacts directly with the N-terminal region of the retinoblastoma gene product pRb. Identification of a novel region of pRb-mediating protein interaction. J Biol Chem 270: 22571-22576, 1995
86. Shan B, Zhu X, Chen PL, Durfee T, Yang Y, Sharp D, Lee WH: Molecular cloning of cellular genes encoding retinoblastoma-associated proteins: identification of a gene with properties of the transcription factor E2F. Mol Cell Biol 12: 5620-5631, 1992
87. Tevosian SG, Shih HH, Mendelson KG, Shephard KA, Paulson KE, Yee AS: HBP-1: a HMG box transcriptional repressor that is targeted by the retinoblastoma family. Genes Dev 11: 383-396, 1997
88. Wang C, Petryniak B, Thompson CB, Kaelin WG, Leiden JM: Regulation of the Ets-related transcription factor Elf-1 by binding the retinoblastoma protein. Science 260: 1330-1335, 1993
89. Fan J, Bertino JR: Functional roles of E2F in cell cycle regulation. Oncogene 14: 1191-1200, 1997
90. Dyson N: The regulation of E2F by pRB-family proteins. Genes Dev 12: 2245-2262, 1998
91. Nevins JR: Toward an understanding of the functional complexity of the E2F and retinoblastoma families. Cell Growth Differ 9: 585-593, 1998
92. Kovesdi I, Reichel R, Nevins JR: E1A transcription induction: enhanced binding of a factor to upstream promoter sequences. Science 231: 719-722, 1986
93. Ohtani K, DeGregori J, Nevins JR: Regulation of the cyclin E gene by transcription factor E2F1. Proc Natl Acad Sci USA 92: 12146-12150, 1995
94. Farnham PJ, Schimke RT: Transcriptional regulation of mouse dihydrofolate reductase in the cell cycle. J Biol Chem 260: 7675-7680, 1985
95. Wade M, Blake MC, Jambou RC, Helin K, Harlow E, Azizkhan JC: An inverted repeat motif stabilizes binding of E2F and enhances transcription of the dihydrofolate reductase gene. J Biol Chem 270: 9783-9791, 1995
96. Slansky JE, Li Y, Kaelin WG, Farnham PJ: A protein synthesis-dependent increase in E2F1 mRNA correlates with growth regulation of the dihydrofulate reductase promoter. Mol Cell Biol 12: 5620-5631, 1993
97. DeGregori J, Kowalik T, Nevins JR: Cellular targets for activation by the E2F1 transcription factor include DNA synthesis and G1/S regulatory genes. Mol Cell Biol 15: 4215-4224, 1995
98. Iavarone A, Massague J: E2F and histone deacetylase mediate transforming growth factor beta repression of cdc25 A during keratinocyte cell cycle arrest. Mol Cell Biol 19: 916-922, 1999
99. Furukawa Y, Terui Y, Sakoe K, Ohta M, Saito M: The role of cellular transcription factor E2F in the regulation of cdc2 messenger-RNA expression and cell-cycle control of human hematopoietic-cells. J Biol Chem 269: 26249-26258, 1994
100. Johnson DG, Ohtani K, Nevins JR: Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. Genes Dev 8: 1514-1525, 1994
101. Hsiao KM, McMahon SL, Farnham PJ: Multiple DNA elements are required for the growth regulation of the mouse E2F1 promoter. Genes Dev 8: 1526-1537, 1994
102. Gill RM, Hamel PA, Zhe J, Zacksenhaus E, Gallie BL, Phillips RA: Characterization of the human RB1 promoter and of elements involved in transcriptional regulation. Cell Growth Differ 5: 467-474, 1994
103. Zacksenhaus E, Gill RM, Phillips RA, Gallie BL: Molecular cloning and characterization of the mouse RB1 promoter. Oncogene 8: 2343-2351, 1993
104. Shan B, Chang CY, Jones D, Lee WH: The transcription factor E2F-1 mediates the autoregulation of RB gene expression. Mol Cell Biol 14: 299-309, 1994
105. Zhu L, Zhu L, Xie E, Chang LS: Differential roles of two tandem E2F sites in repression of the human p107 promoter by retinoblastoma and p107 proteins. Mol Cell Biol 15: 3552-3562, 1995
106. Weintraub SJ, Prater CA, Dean DC: Retinolastoma protein switches the E2F site from a positive to a negative element. Nature 358: 259-261, 1992
107. Bremner R, Cohen BL, Sopta M, Hamel PA, Ingles CJ, Gallie BL, Phillips RA: Direct transcriptional repression by pRB and its reversal by specific cyclins. Mol Cell Biol 15: 3256-3265, 1995
108. Magnaghi-Jaulin L, Groisman R, Naguibneva I, Robin P, Lorain S, Le Villain JP, Troalen F, Trouche D, Harel-Bellan A: Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature 391: 601-605, 1998
109. Luo RX, Postigo AA, Dean DC: Rb interacts with histone deacetylase to repress transcription. Cell 92: 463-473, 1998
110. Dagnino L, Fry CJ, Bartley SM, Farnham P, Gallie BL, Phillips RA: Expression patterns of the E2F family of transcription factors during mouse nervous system development. Mech Dev 66: 13-25, 1997
111. Dagnino L, Fry CJ, Bartley SM, Farnham P, Gallie BL, Phillips RA: Expression patterns of the E2F family of transcription factors during murine epithelial development. Cell Growth Differ 8: 553-563, 1997
112. Humbert PO, Verona R, Trimarchi JM, Rogers C, Dandapani S, Lees JA: E2f3 is critical for normal cellular proliferation (in process citation). Genes Dev 14: 690-703, 2000
113. Yamasaki L, Bronson R, Williams BO, Dyson NJ, Harlow E, Jacks T: Loss of E2F-1 reduces tumorigenesis and extends the lifespan of Rb1(+/-)mice. Nat Genet 18: 360-364, 1998
114. Yamasaki L, Jacks T, Bronson R, Goillot E, Harlow E, Dyson N: Tumor induction and tissue atrophy in mice lacking E2F-1. Cell 85: 537-548, 1996
115. Leone G, DeGregori J, Yan Z, Jakoi L, Ishida S, Williams RS, Nevins JR: E2F3 activity is regulated during the cell cycle and is required for the induction of S phase. Genes Dev 12: 2120-2130, 1998
116. DeGregori J, Leone G, Miron A, Jakoi L, Nevins JR: Distinct roles for E2F proteins in cell growth control and apoptosis. Proc Natl Acad Sci USA 94: 7245-7250, 1997
117. Leone G, Nuckolls F, Ishida S, Adams M, Sears R, Jakoi L, Miron A, Nevins JR: Identification of a Novel E2F3 Product Suggests a Mechanism for Determining Specificity of Repression by Rb. Mol Cell Biol 20: 3626-3632, 2000
118. Logan TJ, Evans DL, Mercer WE, Bjornsti MA, Hall DJ: Expression of a deletion mutant of the E2F1 transcription factor in fibroblasts lengthens S phase and increases sensitivity to S phase-specific toxins. Cancer Res 55: 2883-2891, 1995
119. Pan H, Yin C, Dyson NJ, Harlow E, Yamasaki L, Van Dyke T: Key Roles for E2F1 in Signaling p53-Dependent Apoptosis, in Cell Division within Developing Tumors. Mol Cell 2: 283-292, 1998
120. Kowalik TF, DeGregori J, Leone G, Jakoi L, Nevins JR: E2F1-specific induction of apoptosis and p53 accumulation, which is blocked by Mdm2. Cell Growth Differ 9: 113-118, 1998
121. Zacksenhaus E, Jiang Z, Chung D, Marth JD, Phillips RA, Gallie BL: pRb controls proliferation, differentiation, and death of skeletal muscle cells and other lineages during embryogenesis. Genes Dev 10: 3051-3064, 1996
122. Dirks PB, Rutka JT, Hubbard SL, Mondal S, Hamel PA: The E2F-family proteins induce distinct cell cycle regulatory factors in p16-arrested, U343 astrocytoma cells. Oncogene 17: 867-876, 1998
123. Hurford RK Jr, Cobrinik D, Lee MH, Dyson N: pRB and p107/p130 are required for the regulated expression of different sets of E2F responsive genes. Genes Dev 11: 1447-1463, 1997
124. Sardet C, Vidal M, Cobrinik D, Geng Y, Onufryk C, Chen A, Weinberg RA: E2F-4 and E2F-5, two members of the E2F family, are expressed in the early phases of the cell cycle. Proc Natl Acad Sci USA 92: 2403-2407, 1995
125. Kiess M, Gill RM, Hamel PA: Expression and activity of the retinoblastoma protein (pRB)-family proteins, p107 and p130, during L6 myoblast differentiation. Cell Growth Differ 6: 1287-1298, 1995
126. Takahashi Y, Rayman JB, Dynlacht BD: Analysis of promoter binding by the E2F and pRB families in vivo: distinct E2F proteins mediate activation and repression. Genes Dev 14: 804-816, 2000
127. Gill RM, Hamel PA: Subcellular compartmentalization of E2F family members is required for maintenance of the post-mitotic state in terminally differentiated muscle. J Cell Biol 148: 1187-1201, 2000
128. Verona R, Moberg K, Estes S, Starz M, Vernon JP, Lees JA: E2F activity is regulated by cell cycle-dependent changes in subcellular localization. Mol Cell Biol 17: 7268-7282, 1997
129. Yen A, Coder D, Varvayanis S: Concentration of RB protein in nucleus vs. cytoplasm is stable as phosphorylation of RB changes during the cell cycle and differentiation. Eur J Cell Biol 72: 159-165, 1997
130. Moberg K, Starz MA, Lees JA: E2F-4 switches from p130 to p107 and pRB in response to cell cycle reentry. Mol Cell Biol 16: 1436-1449, 1996
131. Krek W, Ewen ME, Shirodkar S, Arany Z, Kaelin WG Jr, Livingston DM: Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase. Cell 78: 161-172, 1994
132. Krek W, Xu G, Livingston DM: Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint. Cell 83: 1149-1158, 1995
133. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88: 323-331, 1997
134. Giaccia AJ, Kastan MB: The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev 12: 2973-2983, 1998
135. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993
136. Barak Y, Juven T, Haffner R, Oren M: mdm2 expression is induced by wild type p53 activity. Embo J 12: 461-468, 1993
137. Kastan MB, Zhan Q, el-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJ Jr: A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71: 587-597, 1992
138. Okamoto K, Beach D: Cyclin G is a transcriptional target of the p53 tumor suppressor protein. Embo J 13: 4816-4822, 1994
139. Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299, 1995
140. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR, Kley N: Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377: 646-649, 1995
141. Ko LJ, Prives C: p53: puzzle and paradigm. Genes Dev 10: 1054-1072, 1996
142. Ginsberg D, Mechta F, Yaniv M, Oren M: Wild-type p53 can down- modulate the activity of various promoters. Proc Natl Acad Sci USA 88: 9979-9983, 1991
143. Mack DH, Vartikar J, Pipas JM, Laimins LA: Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature 363: 281-283, 1993
144. Subler MA, Martin DW, Deb S: Inhibition of viral and cellular promoters by human wild-type p53. J Virol 66: 4757-4762, 1992
145. Fakharzadeh SS, Trusko SP, George DL: Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. Embo J 10: 1565-1569, 1991
146. Chen J, Marechal V, Levine AJ: Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 13: 4107-4114, 1993
147. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, Pavletich NP: Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain (comment). Science 274: 948-953, 1996
148. Momand J, Zambetti GP, Olson DC, George D, Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245, 1992
149. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B: Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362: 857-860, 1993
150. Thut CJ, Goodrich JA, Tjian R: Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev 11: 1974-1986, 1997
151. Chen J, Lin J, Levine AJ: Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol Med 1: 142-152, 1995
152. Montes de Oca Luna R, Wagner DS, Lozano, G: Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378: 203-206, 1995
153. Haupt Y, Maya R, Kazaz A, Oren M: Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299, 1997
154. Kubbutat MH, Jones SN, Vousden KH: Regulation of p53 stability by Mdm2. Nature 387: 299-303, 1997
155. Kubbutat MH, Ludwig RL, Ashcroft M, Vousden KH: Regulation of Mdm2- directed degradation by the C terminus of p53. Mol Cell Biol 18: 5690-5698, 1998
156. Tao W, Levine AJ: Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc Natl Acad Sci USA 96: 3077-3080, 1999
157. Freedman DA, Levine AJ: Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol Cell Biol 18: 7288-7293, 1998
158. Roth J, Dobbelstein M, Freedman DA, Shenk T, Levine AJ: Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. Embo J 17: 554-564, 1998
159. Honda R, Tanaka H, Yasuda H: Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420: 25-27, 1997
160. Honda R, Yasuda H: Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene 19: 1473-1476, 2000
161. Fuchs SY, Adler V, Buschmann T, Wu X, Ronai Z: Mdm2 association with p53 targets its ubiquitination. Oncogene 17: 2543-2547, 1998
162. Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM: Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53 (in process itation). J Biol Chem 275: 8945-8951, 2000
163. Wu X, Bayle JH, Olson D, Levine AJ: The p53-mdm-2 autoregulatory feedback loop. Genes Dev 7: 1126-1132, 1993
164. Shieh SY, Ikeda M, Taya Y, Prives C: DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91: 325-334, 1997
165. Siliciano JD, Canman CE, Taya Y, Sakaguchi K, Appella E, Kastan MB: DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev 11: 3471-3481, 1997
166. Cox LS, Lane, DP: Tumour suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage. Bioessays 17: 501-508, 1995
167. Chehab NH, Malikzay A, Stavridi ES, Halazonetis TD: Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc Natl Acad Sci USA 96: 13777-13782, 1999
168. Mayo LD, Turchi JJ, Berberich SJ: Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53. Cancer Res 57: 5013-5016, 1997
169. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816, 1993
170. Gyuris J, Golemis E, Chertkov H, Brent R: Cdi1, a human G1 and S phase protein phosphatase that associates with cdk2. Cell 75: 791-803, 1993
171. Nakanishi M, Robetorye RS, Adami GR, Pereira-Smith OM, Smith JR: Identification of the active region of the DNA synthesis inhibitory gene p21Sdi1/CIP1/WAF1. Embo J 14: 555-563, 1995
172. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993
173. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ: Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377: 552-557, 1995
174. Polyak K, Waldman T, He TC, Kinzler KW, Vogelstein B: Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev 10: 1945-1952, 1996
175. Gorospe M, Liu Y, Xu Q, Chrest FJ, Holbrook NJ: Inhibition of G1 cyclin-dependent kinase activity during growth arrest of human breast carcinoma cells. Mol Cell Biol 16: 762-770, 1996
176. El-Deiry WS, Harper JW, O'Conner PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang W, Wiman KG, Mercer EW, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW, Vogelstein B: WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169-1174, 1994
177. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D: Induction of WAF1/CIP1 by a p53 independent pathway. Cancer Res 54: 3391-3395, 1994
178. Strasberg Rieber M, Welch DR, Miele ME, Rieber M: p53-independent increase in p21WAF1 and reciprocal down-regulation of cyclin A and proliferating cell nuclear antigen in bromodeoxyuridine-mediated growth arrest of human melanoma cells. Cell Growth Differ 7: 197-202, 1996
179. Loignon M, Fetni R, Gordon AJ, Drobetsky EA: A p53-independent pathway for induction of p21waf1cip1 and concomitant G1 arrest in UV-irradiated human skin fibroblasts. Cancer Res 57: 3390-3394, 1997
180. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF: Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA 92: 5545-5549, 1995
181. Waga S, Hannon GJ, Beach D, Stillman B: The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369: 574-578, 1994
182. Prelich G, Tan CK, Kostura M, Mathews MB, So AG, Downey KM, Stillman B: Functional identity of proliferating cell nuclear antigen and a DNA polymerase-delta auxiliary protein. Nature 326: 517-520, 1987
183. Luo Y, Hurwitz J, Massague J: Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature 375: 159-161, 1995
184. Li R, Waga S, Hannon GJ, Beach D, Stillman B: Differential effects by the p21 CDK inhibitor on PCNA dependent DNA replication and repair. Nature 371: 534-537, 1994
185. Chen J, Jackson PK, Kirschner MW, Dutta A: Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature 374: 386-388, 1995
186. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 366: 701-704, 1993
187. Chen J, Saha P, Kornbluth S, Dynlacht BD, Dutta A: Cyclin-binding motifs are essential for the function of p21CIP1. Mol Cell Biol 16: 4673-4682, 1996
188. Fotedar R, Fitzgerald P, Rousselle T, Cannella D, Doree M, Messier H, Fotedar A: p21 contains independent binding sites for cyclin and cdk2: both sites are required to inhibit cdk2 kinase activity. Oncogene 12: 2155-2164, 1996
189. Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang P, Dobrowolski S, Bai C, Connell CL, Swindell E et al.: Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 6: 387-400, 1995
190. Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature 382: 325-331, 1996
191. Kip1, a cyclin-Cdk inhibitor, links transforming growth factor β and contact inhibition to cell cycle arrest. Genes Dev. 8: 9-22, 1994
192. Kip1, a cyclin-dependent kinase inhibitor and potential mediator of extracellular antimitogenic signals. Cell 78: 59-66, 1994
193. Toyoshima H, Hunter T: p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell 78: 67-74, 1994
194. Hengst L, Dulic V, Slingerland JM, Lees E, Reed SI: A cell cycle regulated inhibitor of cyclin dependent kinases. Proc Natl Acad Sci USA 91: 5291-5295, 1994
195. Mehlen P, Arrigo AP: The serum-induced phosphorylation of mammalian hsp27 correlates with changes in its intracellular localization and levels of oligomerization. Eur J Biochem 221: 327-334, 1994
196. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M: Role of the ubiquitin-proteosome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269: 682-685, 1995
197. Rots NY, Iavarone A, Bromleigh V, Freedman LP: Induced differentiation of U937 cells by 1,25-dihydroxyvitamin D3 involves cell cycle arrest in G1 that is preceded by a transient proliferative burst and an increase in cyclin expression. Blood 93: 2721-2729, 1999
198. Kuniyasu H, Yasui W, Kitahara K, Naka K, Yokozaki H, Akama Y, Hamamoto T, Tahara H, Tahara E: Growth inhibitory effect of interferon-beta is associated with the induction of cyclin-dependent kinase inhibitor p27Kip1 in a human gastric carcinoma cell line. Cell Growth Differ 8: 47-52, 1997
199. Moro A, Calixto A, Suarez E, Arana MJ, Perea SE: Differential expression of the p27Kip1 mRNA in IFN-sensitive and resistant cell lines. Biochem Biophys Res Commun 245: 752-756, 1998
200. Kip1) of cyclin-dependent kinase 4 activation. Cell 79: 487-496, 1994
201. Levenberg S, Yarden A, Kam Z, Geiger B: p27 is involved in N-cadherin-mediated contact inhibition of cell growth and S-phase entry. Oncogene 18: 869-876, 1999
202. Haddad MM, Xu W, Schwahn DJ, Liao F, Medrano EE: Activation of a cAMP pathway and induction of melano-genesis correlate with association of p16(INK4) and p27(KIP1) to CDKs, loss of E2F-binding activity, and premature senescence of human melanocytes. Exp Cell Res 253: 561-572, 1999
203. Suzuki E, Nagata D, Yoshizumi M, Kakoki M, Goto A, Omata M, Hirata Y: Reentry into the cell cycle of contactinhibited vascular endothelial cells by a phosphatase inhibitor. Possible involvement of extracellular signalregulated kinase and phosphatidylinositol 3-kinase. J Biol Chem 275: 3637-3644, 2000
204. Soos TJ, Kiyokawa H, Yan JS, Rubin MS, Giordano A, DeBlasio A, Bottega S, Wong B, Mendelsohn J, Koff A: Formation of p27-CDK complexes during the human mitotic cell cycle. Cell Growth Differ 7: 135-146, 1996
205. Reynisdottir I, Polyak K, lavarone A, Massague J: Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev 9: 1831-1845, 1995
206. Reynisdottir I, Massague J: The subcellular locations of p15(Ink4b) andp27(Kip1) coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev 11: 492-503, 1997
207. Kip1 for restriction point control of the fibroblast cell cycle. Science 272: 877-880, 1996
208. Pagano M, Tam SW, Theodoras AM, Beer RP, Del SG, Chau V, Yew PR, Draetta GF, Rolfe M: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269: 682-685, 1995
209. Nourse J, Firpo E, Flanagan WM, Coats S, Polyak K, Lee MH, Massague J, Crabtree GR, Roberts JM: Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372: 570-573, 1994
210. Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM, Sherr CJ: The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. Embo J 18: 1571-1583, 1999
211. LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A, Harlow E: New functional activities for the p21 family of CDK inhibitors. Genes Dev 11: 847-862, 1997
212. Parry D, Mahony D, Wills K, Lees E: Cyclin D-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibitors. Mol Cell Biol 19: 1775-1783, 1999
213. Tsutsui T, Hesabi B, Moons DS, Pandolfi PP, Hansel KS, Koff A, Kiyokawa H: Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity. Mol Cell Biol 19: 7011-7019, 1999
214. CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 9: 650-662, 1995
215. Kip2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 9: 639-649, 1995
216. Watanabe H, Pan ZQ, Schreiber-Agus N, DePinho RA, Hurwitz J, Xiong Y: Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57KIP2 requires binding to proliferating cell nuclear antigen. Proc Natl Acad Sci USA 95: 1392-1397, 1998
217. Hashimoto Y, Kohri K, Kaneko Y, Morisaki H, Kato T, Ikeda K, Nakanishi M: Critical role for the 310 helix region of p57(Kip2) in cyclin-dependent kinase 2 inhibition and growth suppression. J Biol Chem 273: 16544-16550, 1998
218. Serrano M, Hannon G, Beach D: A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707, 1993
219. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS 3rd, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440, 1994
220. Ink4b is a potential effector of cell cycle arrest mediated by TGFb. Nature 371: 257-261, 1994
221. INK4B genes. Oncogene 11: 635-645, 1995
222. Hirai H, Rouseel MF, Kato J-Y, Ashmun RA, Sherr CJ: Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclein D-dependent kinases, cdk4 and cdk6. Mol Cell Biol 15: 2672-2681, 1995
223. Guan KL, Jenkins CW, Li Y, O'Keefe CL, Noh S, Wu X, Zariwala M, Matera AG, Xiong Y: Isolation and characterization of p19INK4d, a p16-related inhibitor specific to CDK6 and CDK4. Mol Biol Cell 7: 57-70, 1996
224. Brotherton DH, Dhanaraj V, Wick S, Brizuela L, Domaille PJ, Volyanik E, Xu X, Parisini E, Smith BO, Archer SJ, Serrano M, Brenner SL, Blundell TL, Laue ED: Crystal structure of the complex of the cyclin D-dependent kinase Cdk6 bound to the cell-cycle inhibitor p19INK4d (published erratum appears in Nature 1998 Nov 26; 396(6709): 390). Nature 395: 244-250, 1998
225. Russo AA, Tong L, Lee JO, Jeffrey PD, Pavletich NP: Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. Nature 395: 237-243, 1998
226. Hall M, Bates S, Peters G: Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene 11: 1581-1588, 1995
227. Zariwala M, Liu E, Xiong Y: Mutational analysis of the p16 family cyclin-dependent kinase inhibitors p15INK4b and p18INK4c in tumor-derived alleles and primary tumors. Oncogene 12: 451-455, 1996
228. Wick ST, Dubay MM, Imanil I, Brizuela L: Biochemical and mutagenic analysis of the melanoma tumor suppressor gene product, p16. Oncogene 11: 2013-2019, 1995
229. Hirai H, Roussel MF, Kato JY, Ashmun RA, Sherr CJ: Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol 15: 2672-2681, 1995
230. Zindy F, Quelle DE, Roussel MF, Sherr CJ: Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 15: 203-211, 1997
231. Zindy F, Soares H, Herzog KH, Morgan J, Sherr CJ, Roussel MF: Expression of INK4 inhibitors of cyclin D-dependent kinases during mouse brain development. Cell Growth Differ 8: 1139-1150, 1997
232. Zindy F, van Deursen J, Grosveld G, Sherr CJ, Roussel MF: INK4d-deficient mice are fertile despite testicular atrophy. Mol Cell Biol 20: 372-378, 2000
233. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA: Role of the INK4a locus in tumor suppression and cell mortality. Cell 85: 27-37, 1996
234. Franklin DS, Godfrey VL, Lee H, Kovalev GI, Schoonhoven R, Chen-Kiang S, Su L, Xiong Y: CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev 12: 2899-2911, 1998
235. McConnell BB, Gregory FJ, Stott FJ, Hara E, Peters G: Induced expression of p16(INK4a) inhibits both CDK4-and CDK2-associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes. Mol Cell Biol 19: 1981-1989, 1999
236. LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A, Harlow E: New functional activities for the p21 family of CDK inhibitors. Genes Dev 11: 847-862, 1997
237. Tsai L-H, Lees E, Faha B, Harlow E, Riabowol K: The cdk2 kinase is required for the G1-to-S transition in mammalian cells. Oncogene 8: 1593-1602, 1993
238. Jiang H, Chou HS, Zhu L: Requirement of cyclin E-Cdk2 inhibition in p16(INK4a)-mediated growth suppression. Mol Cell Biol 18: 5284-5290, 1998
239. Mitra J, Dai CY, Somasundaram K, El-Deiry WS, Satyamoorthy K, Herlyn M, Enders GH: Induction of p21(WAF1/CIP1) and inhibition of Cdk2 mediated by the tumor suppressor p16(INK4a). Mol Cell Biol 19: 3916-3928, 1999
240. Quelle DE, Zindy F, Ashmun RA, Sherr CJ: Alternative reading frames of the INK4a tumor suppressor gene encode unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993-1000, 1995
241. Robertson KD, Jones PA: The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol Cell Biol 18: 6457-6473, 1998
242. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G, Sherr CJ: Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91: 649-659, 1997
243. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH, Peters G: The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. Embo J 17: 5001-5014, 1998
244. Robertson KD, Jones PA: Tissue-specific alternative splicing in the human INK4a/ARF cell cycle regulatory locus. Oncogene 18: 3810-3820, 1999
245. Weber JD, Kuo ML, Bothner B, DiGiammarino EL, Kriwacki RW, Roussel MF, Sherr CJ: Cooperative signals governing ARF-mdm2 interaction and nucleolar localization of the complex. Mol Cell Biol 20: 2517-2528, 2000
246. Zhang Y, Xiong Y: Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. Mol Cell 3: 579-591, 1999
247. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ: Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 95: 8292-8297, 1998
248. Honda R, Yasuda H: Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. Embo J 18: 22-27, 1999
249. Zhang Y, Xiong Y, Yarbrough WG: ARF promotes MDM2 degradation and stabilizes p53 : ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725-734, 1998
250. Tao W, Levine AJ: P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc Natl Acad Sci USA 96: 6937-6941, 1999
251. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, DePinho RA: The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92: 713-723, 1998
252. Kurokawa K, Tanaka T, Kato J: p19ARF prevents G1 cyclin-dependent kinase activation by interacting with MDM2 and activating p53 in mouse fibroblasts. Oncogene 18: 2718-2727, 1999
253. Quelle DE, Zindy F, Ashmun RA, Sherr CJ: Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993-1000, 1995
254. Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M: The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397: 164-168, 1999
255. Jacobs JJ, Scheijen B, Voncken JW, Kieboom K, Berns A, van Lohuizen M: Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev 13: 2678-2690, 1999
256. Khan SH, Moritsugu J, Wahl GM: Differential requirement for p19ARF in the p53-dependent arrest induced by DNA damage, microtubule disruption, and ribonucleotide depletion (in process citation). Proc Natl Acad Sci USA 97: 3266-3271, 2000
257. de Stanchina E, McCurrach ME, Zindy F, Shieh SY, Ferbeyre G, Samuelson AV, Prives C, Roussel MF, Sherr CJ, Lowe SW: E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev 12: 2434-2442, 1998
258. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, Roussel MF: Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12: 2424-2433, 1998
259. Unnikrishnan I, Radfar A, Jenab-Wolcott J, Rosenberg N: p53 mediates apoptotic crisis in primary Abelson virus-transformed pre- B cells. Mol Cell Biol 19: 4825-4831, 1999
260. Palmero I, Pantoja C, Serrano M: p19ARF links the tumour suppressor p53 to Ras (letter). Nature 395: 125-126, 1998
261. Somasundaram K, MacLachlan TK, Burns TF, Sgagias M, Cowan KH, Weber BL, el-Deiry WS: BRCA1 signals ARF-dependent stabilization and coactivation of p53. Oncogene 18: 6605-6614, 1999
262. Xiao ZX, Chen J, Levine AJ, Modjtahedi N, Xing J, Sellers WR, Livingston DM: Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375: 694-698, 1995
263. Martin K, Trouche D, Hagemeier C, Sorensen TS, La Thangue NB, Kouzarides T: Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 375: 691-694, 1995
264. Huang S, Shin E, Sheppard KA, Chokroverty L, Shan B, Qian YW, Lee EY, Yee, AS: The retinoblastoma protein region required for interaction with the E2F transcription factor includes the T/E1A binding and carboxy-terminal sequences. DNA Cell Biol 11: 539-548, 1992
265. Whitaker LL, Su H, Baskaran R, Knudsen ES, Wang JY: Growth suppression by an E2F-binding-defective retinoblastoma protein (RB): contribution from the RB C pocket. Mol Cell Biol 18: 4032-4042, 1998
266. Hiebert SW: Regions of the Retinoblastoma gene product required for its interaction with the E2F transcription factor are necessary for E2-promoter repression and pRB-mediated growth suppression. Molecular and Cellular Biology 13: 3384-3391, 1993
267. Sun P, Dong P, Dai K, Hannon GJ, Beach D: p53-independent role of MDM2 in TGF-betal resistance. Science 282: 2270-2272, 1998
268. Carnero A, Hudson JD, Price CM, Beach DH: p16INK4A and p19ARF act in overlapping pathways in cellular immortalization (in process citation). Nat Cell Biol 2: 148-155, 2000
269. Hsieh JK, Chan FS, O'Connor DJ, Mittnacht S, Zhong S, Lu X: RB regulates the stability and the apoptotic function of p53 via MDM2. Mol Cell 3: 181-193, 1999
270. Xiao ZX, Chen J, Levine AJ, Modjtahedi N, Xing J, Sellers WR, Livingston DM: Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375: 694-698, 1995